Th1 inducing natural adjuvant for heterologous antigens
US6936263B2 · kind B2 · utility
10Cited by
10References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2002 |
| Grant date | Aug 30, 2005 |
| Priority date | — |
| Expiry date | Aug 23, 2022 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/829
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.